Koers NicOx SA Euronext Paris
Aandelen
NCOX
FR0000074130
Farmaceutische producten
Omzet 2023 | 4,2 mln. 4,49 mln. | Omzet 2024 * | 9,2 mln. 9,84 mln. | Marktkapitalisatie | 18,7 mln. 20 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2023 * | -15 mln. -16,04 mln. | Nettowinst (verlies) 2024 * | -14 mln. -14,97 mln. | EV/omzet 2023 | 5,25 x |
Nettoschuld 2023 * | 9,24 mln. 9,88 mln. | Nettoliquiditeiten 2024 * | - 0 | EV/omzet 2024 * | 2,03 x |
K/w-verhouding 2023 * |
-1,25
x | K/w-verhouding 2024 * |
-1,56
x | Werknemers | - |
Dividendrendement 2023 * |
-
| Dividendrendement 2024 * |
-
| Vrij verhandelbaar | 93,38% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Gavin M. Spencer
CEO | Chief Executive Officer | 53 | 01-01-05 |
Michele Garufi
FOU | Founder | 70 | 15-02-96 |
Sandrine Gestin
DFI | Director of Finance/CFO | 56 | 01-01-99 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Les Kaplan
BRD | Director/Board Member | 73 | 01-10-14 |
Director/Board Member | 65 | 18-05-17 | |
Adrienne Graves
BRD | Director/Board Member | 69 | 08-08-14 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+5,31% | 70,44 mld. | |
+10,97% | 8,94 mld. | |
-16,83% | 4,75 mld. | |
+43,48% | 4,5 mld. | |
+3,20% | 3,85 mld. | |
+18,82% | 2,38 mld. | |
-21,36% | 2,34 mld. | |
-29,67% | 2,2 mld. | |
+8,38% | 1,96 mld. |